Novartis
NEWS
Shares of Novartis are down nearly 3 percent this morning after the company reported a sharp decline in generic drugs and sales results from key branded medicines that missed analysts’ projections for the first quarter.
Novartis announced that John Tsai, formerly of Amgen, is joining the company as Head of Global Drug Development and chief medical officer.
GlaxoSmithKline Chief Executive Officer Emma Walmsley continues to hone her leadership team with a hire who will focus on potential research and development deals.
Amgen announced final data from its Phase IIIb LIBERTY clinical trial of Aimovig (erenumab), with positive results likely to lead to a blockbuster drug for migraine sufferers.
Mosquito-borne illnesses are a major concern in many parts of the world. One of the nastier viruses carried by mosquitoes, malaria, was responsible for the deaths of more than 445,000 people in 2016. One biotech is aiming to make a difference.
Mylan Rumored to be in Discussions to Buy Merck KGaA’s Consumer Health Business, but Mylan Denies It
Mylan is reportedly in top-level talks with Germany’s Merck KGaA to buy its consumer health business. However, Mylan has denied it.
Switzerland-based Novartis is buying Bannockburn, Illinois-based AveXis for $8.7 billion. This could spell big trouble for Cambridge, Massachusetts-based Biogen.
Novartis has struck a deal to acquire AveXis for $8.7 billion. Novartis will pay $218 per share, which is a 72 percent premium over AveXis’s 30-day volume-weighted average stock price.
Shares of Conatus Pharmaceuticals dropped 34.3 percent postmarket yesterday after the San Diego-based company announced mixed top-line results for its proof-of-concept trial in liver transplant patients with fibrosis or cirrhosis.
JOBS
IN THE PRESS